Saterinone
CAS: 102669-89-6
Ref. 3D-CEA66989
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Product Information
- Saterinone [INN]
- (+-)-1,2-Dihydro-5-(p-(2-hydroxy-3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-6-methyl-2-oxonicotinonitrile
- Saterinona
- Saterinona [Spanish]
- Saterinonum
- Saterinonum [Latin]
- Unii-W4P85Fo7Gs
- 5-(4-{2-Hydroxy-3-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Propoxy}Phenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carbonitrile
Saterinone is a cardiac glycoside that binds to the beta-adrenergic receptor. Saterinone has been shown to reduce the incidence of cancer and bowel disease in rats, as well as the severity of bowel disease. It is also used for the treatment of congestive heart failure and inflammatory bowel disease. This drug has inhibitory properties on isolated heart muscle cells, which are mediated by its ability to bind to the beta-adrenergic receptor. Furthermore, saterinone may have a role in blood pressure monitoring because it inhibits angiotensin II-induced contraction of isolated vascular smooth muscle cells.
Saterinone is an inhibitor of nitroprusside-induced hypotension in rabbits, which may be due to its ability to inhibit nitric oxide synthase (NOS).
Chemical properties
Technical inquiry about: 3D-CEA66989 Saterinone
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
